Shares in Clough family-backed NeuroScientific Biopharmaceuticals have plunged after a planned clinical trial for its budding Alzheimer’s treatment was rejected by the Human Research Ethics Committee.

Shares in Clough family-backed NeuroScientific Biopharmaceuticals have plunged after a planned clinical trial for its budding Alzheimer’s treatment was rejected by the Human Research Ethics Committee.